Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma

NCT02927964 is registered in ClinicalTrials.gov with Robert Lowsky as lead sponsor.

NCT NCT02927964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02927964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Lead sponsor
Robert Lowsky
Phase
Phase 1/2
Overall status
Completed
Start date
November 7, 2016
Completion date
May 18, 2023
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, recurrent follicular lymphoma, refractory follicular lymphoma